MassVentures' START program awarded Theromics Inc. funding to advance technologies, including an injectable nanogel for cancer ablation and drug delivery.
Theromics Inc. appointed Ron Murphy as CEO, effective April 18, 2019, succeeding Thomas Ryan, and welcomed Dr. Joseph Amaral to its Board of Directors. Murphy said he would work with Dr. Dupuy and Dr. Park to commercialize technologies for thermal ablation.
Theromics appointed Andrew C. Zeringue as CEO. Zeringue has nearly 20 years of leadership experience in interventional oncology and thermal ablation and will guide growth as Theromics advances its HeatSYNC gel platform toward FDA clearance.
Theromics Inc. received an NSF STTR Phase I grant to advance HeatSYNC, a thermal accelerant gel designed for interventional radiology. The gel expands soft tissue ablation treatment areas for minimally invasive tumor treatments.
